Melior Capital Management is a Swiss domiciled fund introduction and advisory firm focused exclusively on the global life-science sector.
Melior was founded by an experienced group of individuals who understood that there was a real opportunity for a stirringly new approach to financing within the life-science sector by building a renowned world class team of experts from the sector, minimising commercial risks and mitigating operational risks with the highest levels of due diligence and by aligning the interests of all parties, including the investee, investor and professional intermediaries.
Melior’s scientific team are the bedrock of our success. They have a proven, publicly verifiable, track record of having taken over sixty drugs and medtech projects to market during their careers, including a number of multi-billion dollar blockbusters. Our scientific team have all remained with the business and include European and US Government advisors (including the US FDA) advisor’s to the Wellcome Trust and the Cambridge Colleges, a leading oncology researcher and a trustee for the Institute of Cancer Research.